英文原著論文・総説
2024年
Yamasaki S, Shimizu K, and Fujii S. Tumor epitope spreading by a novel multivalent therapeutic cellular vaccine targeting cancer antigens to invariant NKT-triggered dendritic cells in situ. Front Immunol. 2024, 15: 1345037.
Fujii S, Shimizu K. NKT-licensed in vivo dendritic cell-based immunotherapy as cellular immunodrugs for cancer treatment. Critical Reviews in Oncogenesis. 2024, 29(1):45-61. [review]
2023年
Iyoda T, Shimizu K, Endo T, Watanabe T, Taniuchi I, Aoshima H, Satoh M, Nakazato H, Yamasaki S, Fujii S. Zeb2 regulates differentiation of long-lived effector of invariant NKT cells. Commun Biol 2023, 6:1070.
Shimizu K, Ueda S, Kawamura M, Aoshima H, Satoh M, Nakabayashi J, Fujii S. Combination of cancer vaccine with CD122-biased IL-2/anti-IL-2 Ab complex shapes the stem-like effector NK and CD8+ T cells against tumor. J Immunother Cancer. 2023, 11(7):e006409.
Okada M, Shimizu K, Nakazato H, Yamasaki S, Fujii S. Detection of mutant antigen-specific T cell receptors against multiple myeloma for T cell engineering. Mol. Ther. Methods Clin. Dev. 2023, 29:541-555.
Iyoda T, Yamasaki S, Ueda S, Shimizu K, Fujii S. Natural Killer T and Natural Killer Cell-Based Immunotherapy Strategies Targeting Cancer. Biomolecules. 2023, 13(2):348. [review]
Iyoda T, Shimizu K, Kawamura M, Shinga J, Watanabe T, Fukunaga K, Nushiroda T, Saka H, Kitagawa C, Shimamatsu S, Takenoyama M, Suehiro Y, Imai T, Shingani A, Ito S and Fujii S. Augmenting granzyme B-expressing NK cells by iNKT ligand-loaded antigen-presenting cells in patients with post operative early stage non-small cell lung cancer: Results of a randomized phase II study. Immuno Horizons. 2023, 7(1):1-16.
2022年
Fujii S, Kawamata T, Shimizu K, Nakabayashi J, Yamasaki S, Iyoda T, Shinga J, Nakazato H, Sanpei A, Kawamura M, Ueda S, Dörrie J, Mojsov S, Dhodapkar MV, Hidaka M, Nojima M, Nagamura F, Yoshida S, Goto T, Tojo A. Reinvigoration of innate and adaptive immunity integrated via cellular immunotherapy for relapsed and refractory AML. Molecular Ther Oncolytics. 2022, 27:315-332
Shimizu K, Ueda S, Kawamura M, Satoh M, Fujii S. A single immunization with cellular vaccine confers dual protection against SARS-CoV-2 and cancer. Cancer Sci. 2022, 113(8):2536-2547.
Fujii S, Yamasaki S, Hanada K, Ueda S, Kawamura M and Shimizu K. Cancer immunotherapy using artificial adjuvant vector cells to deliver NY-ESO-1 antigen to dendritic cells in situ. Cancer Sci. 2022, 113:864.
Fujii S, Yamasaki S, Iyoda T, Shimizu K. Association of cellular immunity with severity of COVID-19 from the perspective of antigen-specific memory T cell responses and cross-reactivity. Inflamm Regen. 2022, 42(1):50-63. [review]
Okada M, Shimizu K, Fujii S. Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy. Int J Mol Sci. 2022, 23(5):2594-2611. [review]
2021年
Shimizu K, Iyoda T, Sanpei A, Nakazato H, Okada M, Ueda S, Kato-Murayama M, Murayama K, Shirouzu M, Harada N, Hidaka M and Fujii S. Identification of TCR repertoires in functionally competent cytotoxic T cells cross-reactive to SARS-CoV-2. Commune Biol. 2021, 4:1365-1378.
Miyauchi K, Adachi Y, Tonouchi K, Yajima T, Harada Y, Fukuyama H, Deno S, Iwakura Y, Yoshimura A, Hasegawa H, Yugi K, Fujii S, Ohara O, Takahashi Y, and Kubo M. Influenza virus infection expands the breadth of antibody responses through IL-4 signaling in B cells. Nat Commun. 2021, 12:3789-3804.
2020年
W, Shimizu K, Kojo S, Okeke A, Kohwi-Shigematsu T, Fujii S, Taniuchi I. Runx-mediated regulation of CCL5 via antagonizing two enhancers influences immune cell function and anti-tumor immunity. Nat Commun. 2020, 11:1562-1578.
Okada M, Shimizu K, Iyoda T, Ueda S, Shinga J, Mochizuki Y, Watanabe T, Ohara O, Fujii S. PD-L1 Expression Affects Neoantigen Presentation. iScience. 2020, 23:101238.
Shimizu K, Iyoda T, Yamasaki S, Kadowaki N , Tojo A and Fujii S. NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies. Cancers. 2020, 12:E817. [review]
2019年
Shimizu K, Yamasaki S, Sakurai M, Yumoto N, Ikeda M, Mishima-Tsumagari C, Kukimoto-Niino M, Watanabe T, Kawamura M, Shirouzu M, Fujii S. Granzyme A Stimulates pDCs to Promote Adaptive Immunity via Induction of Type I IFN. Front Immunol. 2019, 10:1450.
Shimizu K, Sato Y, Kawamura M, Nakazato H, Watanabe T, Ohara O & Fujii S. Eomes transcription factor is required for the development and differentiation of invariant NKT cells. Commun Biol. 2019, 2:150.
Iyoda T, Yamasaki S, Kawamura M, Ueda M, Son K, Shimizu K, Fujii S. Optimal therapeutic strategy using antigen-containing liposomes selectively delivered to antigen-presenting cells. Cancer Sci. 2019, 110:875-887.
Ueda M, Seo S, Nair BG, Müller S, Takahashi E, Arai T, Iyoda T, Fujii S, Tsuneda S, Ito Y. End-Sealed High Aspect Ratio Hollow Nanotubes Encapsulating an Anticancer Drug: Torpedo-Shaped Peptidic Nanocapsules. ACS nano. 2019, 13:305-312.
Matsuda M, Ono R, Iyoda T, Endo T, Iwasaki M, Tomizawa-Murasawa M, Saito Y, Kaneko A, Shimizu K, Yamada D, Ogonuki N, Watanabe T, Nakayama M, Koseki Y, Kezuka-Shiotani F, Hasegawa T, Yabe H, Kato S, Ogura A, Shultz LD, Ohara O, Taniguchi M, Koseki H, Fujii S, Ishikawa F. Human NK cell development in hIL-7 and hIL-15 knockin NOD/SCID/IL2rgKO mice. Life Sci Alliance. 2019, 2(2): e201800195.
Fujii S, Shimizu K. Immune Networks and Therapeutic Targeting of iNKT Cells in Cancer. Trends Immunol. 2019, 40: 984-997. [review]
2018年
Iyoda T, Yamasaki S, Hidaka M, Kawano F, Abe Y, Suzuki K, Kadowaki N, Shimizu K, Fujii S. Amelioration of NK cell function driven by Vα24(+) invariant NKT cell activation in multiple myeloma. Clin Immunol. 2018, 187:76-84.
Shimizu K, Iyoda T, Okada M, Yamasaki S, Fujii S. Immune suppression and reversal of the suppressive tumor microenvironment. Int Immunol. 2018, 30(10):445-454. [review]
Fujii S, Yamasaki S, Sato Y, Shimizu K. Vaccine Designs Utilizing Invariant NKT-Licensed Antigen-Presenting Cells Provide NKT or T Cell Help for B Cell Responses. Front Immunol. 2018, 9:1267. [review]
2017年
Harrer DC, Simon B, Fujii S, Shimizu K, Uslu U, Schuler G, Gerer KF, Hoyer S, Dörrie J, Schaft N. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma. BMC Cancer. 2017, 17(1):551.
Yamada D, Iyoda T, Shimizu K, Sato Y, Koseki H and Fujii S. Efficient production of functional human NKT cells from induced pluripotent stem cells-reprogramming of human Vα24+ iNKT cells. Bio Protoc. 2017, 7(10).
Fujii S and Shimizu K. Exploiting antitumor immunotherapeutic novel strategies by deciphering the cross talk between invariant NKT cells and dendritic cells. Front Immunol. 2017, 8:886-893. [review]
2016年
Yamada D, Iyoda T, Vizcardo R, Shimizu K, Sato Y, Endo TA, Kitahara G, Okoshi M, Kobayashi M, Sakurai M, Ohara O, Taniguchi M, Koseki H, Fujii S. Efficient regeneration of Human Vα24+ invariant NKT cells and their anti-tumor activity in vivo. Stem Cells 2016, 34(12):2852-2860.
Yamasaki S, Shimizu K, Kometani K, Sakurai M, Kawamura M, and Fujii S. In vivo dendritic cell targeting cellular vaccine induces CD4+ Tfh cell-dependent antibody against influenza virus. Sci Rep. 2016, 6:35173-35188.
Shimizu K, Yamasaki S, Shinga J, Sato Y, Watanabe T, Ohara O, Kuzushima K, Yagita H, Komuro Y, Asakura M, and Fujii S. Systemic DC activation modulates the tumor microenvironment and shapes the long-lived tumor-specific memory mediated by CD8+ T cells. Cancer Res. 2016, 76:3756-66.
Li Y, Takahashi Y, Fujii S, Zhou Y, Hong R, Suzuki A, Tsubata T, Hase K, Wang JY. EAF2 mediates germinal center B-cell apoptosis to suppress excessive immune responses and prevent autoimmunity. Nat Commun. 2016, 3:10836.
2015年
Shimizu K, Shinga J, Yamasaki S, Kawamura M, Dörrie J, Schaft N, Sato Y, Iyoda T,
Fujii S. Transfer of mRNA Encoding Invariant NKT Cell Receptors Imparts Glycolipid Specific Responses to T Cells and γδT Cells. PLoS One. 2015, 10(6):e0131477.
Sato Y, Shimizu K, Shinga J, Hidaka M, Kawano F, Kakimi K, Yamasaki S, Asakura M, Fujii S. Characterization of the myeloid-derived suppressor cell subset regulated by NK cells in malignant lymphoma. OncoImmunol. 2015, 4:e995541.
Fujii S, Shinga J, Yamsaki S, Sato Y, Asakura M, Shimizu K. In vivo targeting of dendritic cells with artificial adjuvant vector cells (aAVC) as a novel cancer immunotherapy. In Seya T, Udaka K, Matsumoto M, and Sato N (eds), Inflammation and Immunity in Cancer Springer Japan KK, Tokyo, p159-164, 2015. [review]
2014年
Shimizu K, Sato Y, Shinga J, Watanabe T, Endo T, Asakura M, Yamasaki S, Kawahara K, Kinjo Y, Kitamura H, Watarai H, Ishii Y, Tsuji M, Taniguchi M, Ohara O, Fujii S. KLRG+ invariant natural killer T cells are long-lived effectors. Proc Natl Acad Sci U S A. 2014, 111:12474-9.
Hosoi A, Matsushita H, Shimizu K, Fujii S, Ueha S, Abe J, Kurachi M, Maekawa R, Matsushima K, Kakimi K. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells. Int. J. Cancer 2014, 134:1810-1822.
Hasegawa H, Yamashita K, Otubo D, Fujii S, Kamigaki T, Kuroda D, Kakeji Y. Allogeneic DCG promote lung NK cell activation and antitumor effect after invariant NKT cell activation. Anticancer Res. 2014, 34:3411-3417.
2013年
Shimizu K, Asakura M, Shinga J, Sato Y, Kitaha Shimizu K, Asakura M, Shinga J, Sato Y, Kitahara S, Hoshino K, Kaisho T, Schoenberger SP, Ezaki T, Fujii S. Invariant NKT cells induce plasmacytoid DC cross-talk with conventional DCs for efficient memory CD8+ T cell induction. J Immunol. 2013, 190:5609-5619.
Vizcardo R, Masuda K, Yamada D, Ikawa T, Shimizu K, Fujii S, Koseki H, Kawamoto H. Regeneration of antigen-specific T cells from iPS cells derived from human CD8+ mature T cells. Cell Stem Cell 2013, 12:31-36.
Shimizu K, Mizuno T, Shinga J, Asakura M, Kakimi K, Ishii Y, Masuda K, Maeda T, Sugahara H, Sato Y, Matsushita H, Nishida K, Hanada KI, Dörrie J, Schaft N, Bickham K, Koike H, Ando T, Nagai R, Fujii S. Vaccination with antigen-transfected, NKT cell ligand-loaded, human cells elicits robust in situ immune responses by dendritic cells. Cancer Res. 2013, 73:62-73.
Fujii S, Shimizu K, Okamoto Y, Kunii N, Nakayama T, Motohashi S, Taniguchi M. NKT Cells as an Ideal Anti-Tumor Immunotherapeutic. Front Immunol. 2013, 4:409. [review]
Fujii S and Shimizu K. Immunotherapy with artificial adjuvant vector cells (aAVCs): harnessing both arms of the immune response. OncoImmunol. 2013, 2:e23432. [review]
2012年
Nagato K, Motohashi S, Ishibashi F, Okita K, Yamasaki K, Moriya Y, Hoshino H, Yoshida S, Hanaoka H, Fujii S, Taniguchi M, Yoshino I, Nakayama T. Accumulation of activated invariant natural killer T cells in the tumor microenvironment after α-galactosylceramide-pulsed antigen presenting cells. J Clin Immunol. 2012, 32:1071-81.
Watarai H, Yamada D, Fujii S, Taniguchi M, Koseki H. Induced pluripotency as a potential path towards iNKT cell-mediated cancer immunotherapy. Int J Hematol. 2012, 95:624-31. [review]
Taniguchi M, Fujii S, Nakayama T, Motohashi S, Dashtsoodol N, Watarai H, and Harada M. Introduction: Mechanisms of NKT-cell-mediatd adjuvant activity and function of iPS-derived NKT cells. In Terabe M and Berzofsky JA(eds). Natural killer T cells: Balancing the regulation of tumor immunity. Springer New York Dordrecht Heidelberg London, p1-14, 2012. [review]
2011年
Shimizu K, Asakura M, Fujii S. Prolonged antitumor NK cell reactivity elicited by CXCL-10-expressing dendritic cells licensed by CD40L+CD4+ memory T cells. J. Immunol. 2011, 186:5927-37.
Asano K, Nabeyama A, Miyake Y, Qiu CH, Kurita A, Tomura M, Kanagawa O, Fujii S, Tanaka M. CD169-Positive Macrophages Dominate Antitumor Immunity by Crosspresenting Dead Cell-Associated Antigens. Immunity. 2011, 34:85-95.
Fujii S and Shimizu K. “DC-based immunotherapy targeting NKT cells.” In Berzofsky JA, Terabe M, editors. Natural killer T cells: Balance the regulation of tumor immunity. New York, NY Springer, p95-110, 2011. [review]
2010年
Okita K, Motohashi S, Shinnakasu R, Nagato K, Yamasaki K, Sato Y, Kitamura H, Hijikata A, Yamashita M, Shimizu K, Fujii S, Ohara O, Taniguchi M, Sakaida I, Nakayama T. A set of genes associated with the interferon-γ response of lung cancer patients undergoing α-galactosylceramide-pulsed dendritic cell therapy. Cancer Sci. 2010, 101:2333-40.
Watarai H, Fujii S, Yamada D, Rybouchkin A, Sakata S, Nagata Y, Iida-Kobayashi M, Sekine-Kondo E, Shimizu K, Shozaki Y, Sharif J, Matsuda M, Mochiduki S, Hasegawa T, Kitahara G, Endo TA, Toyoda T, Ohara O, Harigaya K, Koseki H, Taniguchi M. Murine induced pluripotent stem cells can be derived from and differentiate into natural killer T cells. J Clin Invest. 2010, 120:2610-8.
Tashiro T, Sekine-Kondo E, Shigeura T, Nakagawa R, Inoue S, Omori-Miyake M, Chiba T, Hongo N, Fujii S, Shimizu K, Yoshiga Y, Sumida T, Mori K, Watarai H and Taniguchi M. Induction of Th1-biased cytokine production by carba-GalCer, a neoglycolipid ligand for NKT cells. Int Immunol. 2010, 22, 319-28.
Ikeuchi N, Futami J, Hosoi A, Noji S, Kurachi M, Ueha S, Fujii S, Yamada H, Matsushima K, Moriyasu F, Kakimi K. Efficient cross-presentation of soluble exogenous antigens introduced into dendritic cells using a weak-based amphiphilic peptide. Biochem Biophys Res Commun. 2010, 392:217-22.
Shimizu K, Hidaka M, Bickham K, Moriwaki M, Fujimoto K, Kawano F, Fujii S. Human leukemic cells loaded with alpha-galactosylceramide (alpha-GalCer) activate murine NKT cells in situ. Int J Hematol. 2010, 92:152-60.
Watarai H, Rybouchkin A, Hongo N, Nagata Y, Sakata S, Sekine E, Dashtsoodol N, Tashiro T, Fujii S, Shimizu K, Mori K, Masuda K, Kawamoto H, Koseki H, Taniguchi M. Generation of functional NKT cells in vitro from embryonic stem cells bearing rearranged invariant Valpha14-Jalpha18 TCRalpha gene. Blood 2010, 115:230-7.
Ishii Y, Motohashi S, Shimizu K, Nakayama Taniguchi M, and Fujii S. Application of NKT cells in immunotherapy. Curr Immunol review. 2010, 6:109-115. [review]
Fujii S, Motohashi S, Shimizu K, Nakayama T, Yoshiga Y, Taniguchi M. Adjuvant activity mediated by iNKT cells. Semin Immunol. 2010, 22:97-102. [review]
2009年
Fujii S, Goto A, Shimizu K. Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity. Blood 2009, 113:4262-72.
Shimizu K and Fujii S. Dendritic cell therapy induces long term NK reactivity to tumors via host dendritic cells. Eur J Immunol. 2009, 39:457-68.
Fujii S, Takayama T, Asakura M, Aki K, Fujimoto K, Shimizu K. Dendritic cell-based cancer immunotherapies. Arch Immunol Ther Exp (Warsz). 2009, 57:189-98. [review]
2008年
Shimizu K, Fujii S. An adjuvant role of in situ dendritic cells (DCs) in linking innate and adaptive immunity. Front Biosci. 2008, 13:6193-201. [review]
Fujii S. Exploiting dendritic cells (DCs) and NKT cells in immunotherapy against malignancies. Trends Immunol. 2008, 29:242-9. [review]
2007年
Shimizu K, Kurosawa Y, Taniguchi M, Steinman RM, Fujii S. Cross-presentation of glycolipid from tumor cells loaded with -galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J Exp Med. 2007, 204:2641-53.
Ishikawa F, Niiro H, Iino T, Yoshida S, Saito N, Onohara S, Miyamoto H, Minagawa H, Fujii S, Shultz LD, Harada M, Akashi K. The development program of human dendritic cells is operated independently of conventional myeloid and lymphoid pathways. Blood. 2007, 110:3591-660.
Shimizu K, Goto A, Fukui K, Taniguchi M, Fujii S. Tumor Cells Loaded with-Galactosylceramide Induce Innate NKT and NK Cell-Dependent Resistance to Tumor Implantation in Mice. J Immunol. 2007, 178:2853-61.
Fujii S, Shimizu K, Hemmi H, Steinman RM. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity. Immunol Rev. 2007, 220:183-98. [review]
Fujii S and Lotze, MT. “IL-10 and cancer” In: Lotze MT, Caligiuri MA editors. Cytokines in the genesis and treatment of cancer. Totowa, NH: Humana Press, 2007. [review]
2006年
Shimizu K, Hidaka M, Kadowaki N, Makita N, Konishi N, Fujimoto K, Uchiyama T, Kawano F, Taniguchi M, Fujii S. Evaluation of the function of human invariant NKT cells from cancer patients using galactosylceramide-loaded murine dendritic cells. J Immunol. 2006, 177:3484-92.
Fujii S, Shimizu K, Hemmi H, Fukui M, Bonito AJ, Chen G, Franck RW, Tsuji M, Steinman RM. Glycolipid -C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc Natl Acad Sci U S A. 2006, 103:11252-11257.
Motohashi S, Ishikawa A, Ishikawa E, Otsuji M, Lizasa T, Hanaoka H, Horiguchi S, Okamoto Y, Fujii S, Taniguchi M, Fujisawa T, Nakayama T. A phase I study of in vitro expanded NKT cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res. 2006, 202:203-207.
Fujii S and Lotze, M.T. “IL-10 effects on innate immunity” In: Marincola FM editor. “Interleukin-10” Austin, TX: Landes Bioscience, 2006. p.11-23
2005年
Fujii S, Nishimura MI, Lotze MT. Regulatory balance between the immune response of tumor antigen-specific TCR gene-transduced CD8+T cells and the suppressive effects of tolerogenic dendritic cells. Cancer Sci. 2005, 96:897-902.
Liu K, Idoyaga J, Charalambous A, Fujii S, Bonito A, Mordoh J, Wainstok R, Bai XF, Liu Y, Steinman RM. Innate NKT lymphocytes confer superior adaptive immunity via tumor capturing dendritic cells. J Exp Med. 2005, 202:1507-1516.
Munz C, Steinman RM, Fujii S. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med. 2005, 202:203-207. [Review]
Steinman RM, Bonifaz L, Fujii S, Liu K, Bonnyay D, Yamazaki S, Pack M, Hawiger D, Iyoda T, Inaba K, and Nussenzweig MC. The innate functions of dendritic cells in peripheral lymphoid tissues. Advances in Experimental Medicine and Biology. 2005, 560:83-97. [Review]
Fujii S. Application of natural killer-T (NKT) cells to post transplant immunotherapy. Int J Hematol. 2005, 81:1-5. [review]
Seino K, Fujii S, Harada M, Motohashi S, Nakayama T, Fujisawa T, and Taniguchi M. [Review] V14 NKT cell-mediated antitumor responses and their clinical application. Springer Semin Immunopathol. 2005, 27:65-74.
2004年
Fujii S, Liu K, Smith C, Bonito AJ, and Steinman RM. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med. 2004, 199:1607-1618.
Bonifaz L, Bonnyay D, Charalambous A, Darguste D, Fujii S, Brimnes M, Moltedo B, Moran T, and Steinman RM. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med. 2004, 199:815-824.
2003年
Fujii S, Shimizu K, Smith C, Bonifaz L, and Steinman RM. Activation of natural killer T cells by galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a co-administered protein. J Exp Med. 2003, 198:267-279.
Fujii S, Shimizu K, Klimek V, Geller MD, Nimer SD, and Dhodapkar MV. Severe and selective deficiency of interferon producing natural killer T cells in patients with myelodysplastic syndromes. Br J Haematol. 2003, 122:617-622.
Dhodapkar MV, Geller MD, Chang DH, Shimizu K, Fujii S, Dhodapkar KM, and Krasovsky J. A reversible defect in natural killer T (NKT) cell function characterizes the progression of premalignant multiple myeloma. J Exp Med. 2003, 197:1667-1676.
Fujii S, Shimizu K, Steinman RM, and Dhodapkar MV. Detection and activation of human V24+NKT cells using galactosylceramide-pulsed dendritic cells. J Immunol Methods. 2003, 272:147-159.
Fujii S, Shimizu K, Fujimoto K, and Kawano F. Malignant counterpart of myeloid dendritic cell (DC) belonging to acute myelogenous leukemia (AML) exhibits a dichotomous immunoregulatory potential. J Leukoc Biol. 2003, 73:82-90.
2002年
Fujii S, Shimizu K, Kronenberg M and Steinman R.M. Prolonged IFN producing NKT response induced with galactosylceramide loaded DCs. Nat Immunol. 2002, 3:867-874.
Masuda M, Senju S, Fujii S, Terasaki Y, Takeya M, Hashimoto S, Matsushima K, Yumoto E, and Nishimura Y. Identification and immunocytochemical analysis of DCNP1, a Denditic cell-associated nuclear protein. Biochem Biophysical Res Commun. 2002, 6202:1022-1029.
2001年
Fujii S, Shimizu K, Shimizu T, and Lotze MT. IL-10 promotes the maintenance of anti-tumor CD8+ T cells effector function in situ. Blood. 2001, 98:2143-2151.
Fujii S, Shimizu K, Fujimoto K, Kiyokawa T, Tsukamoto A, Sanada I, and Kawano F. Treatment of post-transplanted, relapsed patients with hematological malignancies by infusion of HLA-matched, allogeneic-dendritic cells (DCs) pulsed with irradiated tumor cells and primed T cells. Leuk Lymphoma. 2001, 42:357-369.
2000年
Shimizu K, Fujii S, Fujimoto K, Kawa K, and Kawano F. Tacrolimus (FK506) treatment of CD34+ hematopoietic progenitor cells promote the dendritic cells that drive CD4+ T cells toward Th2 responses. J Leukoc Bioly. 2000, 68:633-640.
Fujii S. The interaction between interferon- and clonally expanded T cells in chronic myelogenous leukemia (CML). Leuk lymphoma. 2000, 38:21-38. [review]
1999年
Fujii S, Shimizu K, Fujimoto K, Shimomura T, Taniguchi O, Kinoshita M, and Kawano F. Analysis of a vaccinated chronic myelogenous leukemia patient with leukaemic dendritic cells following autologous peripheral blood stem cell transplantation. Jpn J Cancer Res. 1999, 90:1117-1129.
Fujii S, Hamada H, Fujimoto K, Shimomura T, and Kawakita M. Activated dendritic cells from bone marrow cells receiving cytokine-expressing tumor cells are associated with the enhanced survival of mice bearing synegenic tumors. Blood. 1999, 93:1-9.
Fujii S, Fujimoto K, Shimizu K, Ezaki T, Kawano F, Takatsuki K, Kawakita M, and Matsuno K. Presentation of tumor antigens by phagocytic dendritic cell clusters generated from human CD34+ hematopoietic progenitor cells: Induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogeneous leukemia patients. Cancer Res. 1999, 59:2150-2158.
Simomura T, Fujii S, Ezaki I, Osato M, Fujimoto K, Takatsuki K, Kazuhiko Y, and Kawakita M. Characterization of T cell receptor b chain mRNA expression in IFN responsive chronic myelogeneous leukemia patients. Brit J Haematol. 1999, 105:173-180.
1998年
Fujii S, Fujimoto K, Matsui K, Kawakita M, and Takatsuki K. Induction of antitumor cytotoxic activity using CD34+ cord blood cell-derived and irradiated tumor cell-primed dendritic cells. Int J Hematol. 1998, 68:169-182.
1997年
Morikita T, Maeda Y, Fujii S, Matsushita S, Obaru K, and Takatsuki K. The V1/V2 region of human imunodeficiency virus type 1 modulates the sensitivity to neutralization by soluble CD4 and cellular tropism. AIDS Res Hum Retroviruses. 1997, 13:1291-1299.
Fujii S, Obaru K, Matsushita S, Morikita T, Higuchi H, Fujimoto K, and Takatsuki K. Characterization of proviral DNA from an individual with long-term, nonprogressive infection by human immunodeficiency virus type-1 and nonrecoverable virus. J Acquir Immune Defic Syndr Hum Retrovirol. 1997, 15:247-256.
1996年
Obaru K, Fujii S, Matsushita S, Shimada T, and Takatsuki K. Gene therapy for adult T cell leukemia using human immunodeficiency virus vector carrying the thymidine kinase gene of herpes simplex virus type 1. Hum Gene Ther. 1996, 7:2203-2208.